Cipla Ltd · NSE:CIPLA
Cipla — Q1 FY27 Earnings Presentation
15 slides from Cipla's earnings presentation, Jul 23, 2026
Slide 1: Investor Presentation Q1FY27
Investor Presentation Q1FY27 23-07-2026 1
Slide 2: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual
Slide 3: Delivered the Highest Q1 Revenue
Delivered the Highest Q1 Revenue Revenue EBITDA PAT Q1FY27 INR 7,119 Cr INR 1,192 Cr 16.7% INR 789 Cr 11.1% Margin Margin Business Performance Snapshot Emerging Markets & One India North America One Africa Europe INR 3,452 Cr 12% $ 162 Mn $ 103 Mn 1% $ 106 Mn 5% (YoY) (YoY) (YoY) Q1FY27 Highest-ever
Slide 4: Financial Performance: Q1FY27
Financial Performance : Q1FY27 Revenues INR 7,119 Cr EBITDA 1,192 Cr Revenue1 Break-up Q1FY27 (Consolidated) API and Q1FY27 Q1FY26 Others, 2% (INR Cr) (INR Cr) Emerging markets and Total Revenue from 7,119 6,957 Europe, 14% Operations EBITDA 1,192 1,778 One Africa, EBITDA % 16.7% 25.6% 14% One India
Slide 5: One India: Building a Sustainable Legacy for Enduring Growth
One India1 : Building a Sustainable Legacy for Enduring Growth Highest-ever quarterly revenue of INR 3,452 Cr Branded Prescription Trade Generics Consumer Health ❖ Cipla maintained #2 rank in ❖ Posted steady growth supported ❖ Anchor and transitioned brands overall chronic with chronic mix2 by robus
Slide 6: India Rx: Strengthening Our Journey with Strategic Therapeutic Focus
India Rx : Strengthening Our Journey with Strategic Therapeutic Focus Steady Uptake in Key Therapies1 Growth (%) Rank Largest pharma company by volume Respiratory 13% 1st (units) in market1 Urology 10% 2nd Our in-house brand franchise, Dytor1, has scaled to over INR 700 Cr+ Anti-diabetic 26% 11th Ca
Slide 7: Recent Launches Demonstrate Strong Early Momentum Across Priority Therapies
Recent Launches Demonstrate Strong Early Momentum Across Priority Therapies Neuro-pain brand with an Supportive care brand with a Breath-actuated metered-dose extended-release offering aimed at Oral JAK inhibitor for chronic differentiated combination of inhaler used to manage and treat improving ad
Slide 8: Q1 FY27: Global Consumer Wellness Franchise
Q1 FY27 : Global Consumer Wellness Franchise One India One Africa Consumer Brands in One India Revenue : INR 481 Cr Cold and Cold and Hydration Pain Relief Cough Cough Consumer Brands in Smoking Respi OTC Cold and Flu Skin Infection South Africa Cessation Revenue : ZAR 405 Mn Cold and Respi OTC Coug
Slide 9: North America: Adapting to Evolving Business Dynamics
North America : Adapting to Evolving Business Dynamics Key Business Highlights ▪ gProventil ranked No. 1 with total market1 share at 21% (50 million+ inhaler units supplied to the U.S. market cumulatively) ▪ Launched gVentolin in the U.S. market during the quarter, with initial shipments executed an
Slide 10: ANDA & NDA Portfolio & Pipeline (As on 30th June 2026)
ANDA & NDA Portfolio & Pipeline (As on 30th June 2026) 7 67 9 103 2 2 5 3 23 38 19 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs 1 Cipla Ltd PEPFAR Invagen Partnered ANDAs/NDAs 186 44 48 278 Approved Tentatively Under Approval Total ANDAs & NDAs Approved ANDAs &
Slide 11: One Africa: South Africa Private Growing Faster than the Market
One Africa1 : South Africa Private Growing Faster than the Market SA Key Highlights2 12 18 9 16 ▪ Healthy performance across key therapies like 23 14 Respiratory, CNS and Alimentary TR & Metabolism. ▪ 10 brands with MAT market revenue > 100 Mn ZAR 59 55 ▪ Highest number of brands in top 30 (6), top
Slide 12: Progress on ESG goals (India Manufacturing Operations): Q1FY27
Progress on ESG goals (India Manufacturing Operations) : Q1FY27 Aspects Goals FY 2029-30 Progress Renewable Electricity Share 80% renewable electricity share for India manufacturing 57%* 30% absolute reduction (Scope 1-Energy based & Scope-2) 21% GHG Emissions from baseline of FY2023-24 for Global C
Slide 13: Consolidated Profit and Loss Statement Summary
Consolidated Profit and Loss Statement Summary INR Cr Particulars Q1FY27 Q1FY26 Revenue from sale of products 7,077 6,837 Other operating income 42 120 Income from operations 7,119 6,957 Material cost 2,667 2,171 Employee benefits expense 1,497 1,312 Other expenses 1,762 1,696 Total expenses 5,927 5
Slide 14: Consolidated Balance Sheet
Consolidated Balance Sheet INR Cr Key Balance Sheet Items Jun-26 Jun-25 Equity 34,443 32,665 Total Debt# 600 459 Inventory 6,714 6,091 Cash and Cash Equivalents* 10,094 10,838 Trade Receivables 5,948 6,254 Trade Payables 3,446 3,093 Net Tangible Assets 7,889 6,669 Goodwill and Intangibles 6,928 5,13
Slide 15: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 Diksha Maheshwari Investor.Relations@cipla.com For more information, please visit www.cipla.com 15